Intellia Therapeutics Q3 loss widens to $128M
Existing cash resources were expected to fund operations at least into 2028, excluding potential lonvo-z revenue and future term-loan funding.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Intellia Therapeutics, Inc. (NTLA) reported a third-quarter 2026 net loss of $127.5 million, compared with $101.3 million a year earlier. Collaboration revenue was $7.2 million versus $13.8 million; research and development expense was $83.3 million versus $94.7 million, while general and administrative expense rose to $46.1 million from $30.5 million.
Cash, cash equivalents and marketable securities totaled $614.8 million as of September 30, 2026. Intellia expects existing cash resources to fund operations at least into 2028, excluding potential lonvo-z commercial revenue and future term-loan funding. FDA accepted lonvo-z’s BLA and granted Priority Review, with a March 10, 2027 target action date; Intellia is preparing for a planned first-quarter 2027 commercial launch. Intellia completed MAGNITUDE-2 Phase 3 enrollment in ATTRv-PN, exceeding the 60-patient target, and advanced enrollment in MAGNITUDE for ATTR-CM.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate pointMAGNITUDE-2 completed Phase 3 enrollment, exceeding its 60-patient randomization target.
Negative
- Moderate pointNet loss widened to $127.5 million from $101.3 million.
- Minor pointCollaboration revenue fell to $7.2 million from $13.8 million.
Filing Explained
Intellia says it entered a senior secured term-loan facility for up to
8-K Event Classification
Key Figures
Key Terms
Biologics License Application regulatory
Priority Review regulatory
Prescription Drug User Fee Act regulatory
ATTRv-PN medical
Human leukocyte antigen genotyping medical
Earnings Snapshot
Existing cash resources are expected to fund operations at least into 2028 and well beyond lonvo-z’s anticipated U.S. approval and commercial launch in HAE in the first quarter of 2027; this guidance excludes all potential commercial revenues from lonvo-z and potential future funding from the term loan facility.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much collaboration revenue did NTLA report in Q3 2026?
What is the size of Intellia’s OrbiMed term loan facility?
Is FDA planning an advisory committee for lonvo-z?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2026, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 on this Current Report on Form 8-K.
The information in this report furnished pursuant to Item 2.02 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. |
|
Description |
|
|
|
99.1 |
|
Press release dated November 5, 2026. |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
Intellia Therapeutics, Inc. |
|
|
|
|
Date: |
November 5, 2026 |
By: |
/s/ John M. Leonard |
|
|
|
Name: John M. Leonard |
Exhibit 99.1
Intellia Therapeutics Announces Third Quarter 2026 Financial Results
and Business Updates
CAMBRIDGE, Mass., November 5, 2026 – Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the third quarter ended September 30, 2026.
“This is a defining period for Intellia as we advance our late-stage pipeline and prepare for a transformative year ahead,” said John Leonard, M.D., Intellia President and Chief Executive Officer. “We have assembled the teams and capabilities needed to support a successful launch in HAE while also continuing to advance nex-z’s Phase 3 clinical trials and our pipeline expansion efforts. Looking to 2027, we are working toward a historic milestone: the potential approval of lonvo-z as the world’s first in vivo CRISPR-based therapy. As a one-time treatment, we believe it could transform the HAE treatment paradigm while also delivering significant value to patients, physicians, payers and the overall healthcare system.”
Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
Designed as a one-time treatment that is administered in an outpatient setting, lonvo-z is an in vivo CRISPR gene editing candidate that is intended to inactivate the kallikrein B1 (KLKB1) gene to permanently lower kallikrein and bradykinin levels and to eliminate HAE attacks and the need for lifelong treatment.
Page 1 of 5 |
intelliatx.com |
Nexiguran Ziclumeran (Nex-z) for Transthyretin (ATTR) Amyloidosis
Nex-z is an in vivo CRISPR-based therapeutic candidate designed to inactivate the TTR gene in the liver, thereby preventing the production of transthyretin (TTR) protein. Nex-z offers the possibility of halting and reversing disease by driving a rapid, deep, consistent and potentially lifelong reduction in TTR protein after a one-time treatment. Intellia leads the development and commercialization of nex-z in collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron).
Other Recent Updates
Upcoming Events
The company will participate in the following upcoming events:
Page 2 of 5 |
intelliatx.com |
Third Quarter 2026 Financial Results
About Intellia Therapeutics
Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Forward-Looking Statements
This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These
Page 3 of 5 |
intelliatx.com |
forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the success and advancement of its clinical programs for lonvoguran ziclumeran or “lonvo-z” (previously referred to as NTLA-2002) for the treatment of hereditary angioedema (“HAE”) and nexiguran ziclumeran or “nex-z” (previously referred to as NTLA-2001) for transthyretin (“ATTR”) amyloidosis, including its expectations regarding the review and potential approval by the U.S. Food and Drug Administration its biologics license application (“BLA”) for lonvo-z, its expectations regarding the planned U.S. launch of lonvo-z in the first quarter of 2027, including its ability to complete lonvo-z commercial readiness efforts in advance of the Prescription Drug User Fee Act date of March 10, 2027, and its belief that lonvo-z could transform the HAE treatment paradigm while also delivering significant value to patients, physicians, payers and the overall healthcare system; the potential of lonvo-z to inactivate the KLKB1 gene to permanently lower kallikrein and bradykinin levels and to eliminate HAE attacks and the need for lifelong treatment; the potential of nex-z to inactivate the TTR gene and to halt and reverse disease by driving a rapid, deep, consistent and potentially lifelong reduction in TTR protein after a one-time treatment and to deliver clinically meaningful outcomes for patients; its ability to optimize the impact of its collaborations on its development programs, including, but not limited to, its collaboration with Regeneron Pharmaceuticals, Inc. (“Regeneron”) and their co-development program for ATTR amyloidosis; and its growth as a company and expectations regarding its uses of capital, expenses, future accumulated deficit and financial results, including its expectations regarding its non-dilutive senior secured term loan facility with OrbiMed providing greater financial and operational flexibility and its ability to fund operations at least into 2028 and well beyond lonvo-z’s anticipated U.S. approval and commercial launch in HAE in the first quarter of 2027.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z and nex-z, including risks related to the ability to develop and successfully commercialize lonvo-z, nex-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to the authorization, initiation and conduct of preclinical and clinical studies and other development requirements for its product candidates, including uncertainties related to regulatory approvals to conduct clinical trials; risks related to the results of nonclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; risks related to the potential delay of planned clinical trials due to regulatory feedback or other developments; and risks related to Intellia’s collaborations with Regeneron, or its other collaborations not continuing or not being successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange
Page 4 of 5 |
intelliatx.com |
Commission, including its recent quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.
INTELLIA THERAPEUTICS, INC. |
|
||||||||||||||||||
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) |
|
||||||||||||||||||
(Amounts in thousands, except per share data) |
|
||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
Three Months Ended September 30, |
|
|
Nine Months Ended September 30, |
|
||||||||||
|
|
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
||||
Collaboration revenue |
$ |
7,163 |
|
|
$ |
13,782 |
|
|
$ |
29,870 |
|
|
$ |
44,654 |
|
||||
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Research and development |
|
83,346 |
|
|
|
94,747 |
|
|
|
246,678 |
|
|
|
300,209 |
|
|||
|
General and administrative |
|
46,142 |
|
|
|
30,512 |
|
|
|
118,809 |
|
|
|
86,725 |
|
|||
|
|
Total operating expenses |
|
129,488 |
|
|
|
125,259 |
|
|
|
365,487 |
|
|
|
386,934 |
|
||
Operating loss |
|
(122,325 |
) |
|
|
(111,477 |
) |
|
|
(335,617 |
) |
|
|
(342,280 |
) |
||||
Other (expense) income, net: |
|
|
|
|
|
|
|
|
|
|
|
||||||||
|
Interest income and other, net |
|
5,837 |
|
|
|
6,714 |
|
|
|
16,839 |
|
|
|
22,719 |
|
|||
|
Interest expense |
|
(611 |
) |
|
|
- |
|
|
|
(611 |
) |
|
|
- |
|
|||
|
Change in fair value of investments, net |
|
(10,386 |
) |
|
|
3,439 |
|
|
|
(10,961 |
) |
|
|
2,653 |
|
|||
|
|
Total other (expense) income, net |
|
(5,160 |
) |
|
|
10,153 |
|
|
|
5,267 |
|
|
|
25,372 |
|
||
Net loss |
$ |
(127,485 |
) |
|
$ |
(101,324 |
) |
|
$ |
(330,350 |
) |
|
$ |
(316,908 |
) |
||||
Net loss per share, basic and diluted |
$ |
(0.91 |
) |
|
$ |
(0.92 |
) |
|
$ |
(2.53 |
) |
|
$ |
(2.99 |
) |
||||
Weighted average shares outstanding, basic and diluted |
|
140,186 |
|
|
|
110,188 |
|
|
|
130,802 |
|
|
|
105,841 |
|
||||
INTELLIA THERAPEUTICS, INC. |
|
|||||||
CONSOLIDATED BALANCE SHEET DATA (UNAUDITED) |
|
|||||||
(Amounts in thousands) |
|
|||||||
|
|
|
|
|
|
|
||
|
|
September 30, 2026 |
|
|
December 31, 2025 |
|
||
Cash, cash equivalents and marketable securities |
|
$ |
614,807 |
|
|
$ |
605,134 |
|
Total assets |
|
|
902,560 |
|
|
|
842,127 |
|
Total liabilities |
|
|
289,471 |
|
|
|
170,733 |
|
Total stockholders’ equity |
|
|
613,089 |
|
|
|
671,394 |
|
Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com
Page 5 of 5 |
intelliatx.com |